Preventing Exacerbations of Chronic Bronchitis and COPD
- 1 October 2003
- journal article
- review article
- Published by Springer Nature in American Journal of Respiratory Medicine
- Vol. 2 (5) , 367-370
Abstract
It is important to find interventions that will reduce the frequency and severity of exacerbations of COPD, because of their effect on morbidity and healthcare expenditure. A Cochrane systematic review included 23 studies that had evaluated the effects of treatment with mucolytic agents in patients with chronic bronchitis or COPD. Mucolytic treatment was associated with a significant reduction of 0.79 exacerbations per patient per year compared with placebo, a 29% decrease. Patients who received treatment with mucolytic agents were twice as likely to remain exacerbation-free in the study period than if they had received placebo, with six patients needing regular treatment with mucolytic agents for 3-6 months to achieve one less exacerbation over that time. Treatment with mucolytic agents resulted in nearly 7 days less illness per patient per year. How mucolytic agents work is unknown, although they may reduce exacerbations by altering mucus production, antioxidation, or antibacterial or immunostimulatory effects. They do not appear to affect the decline in lung function that occurs in COPD. The treatment appears to be without any adverse effects, apart from the need to take oral medication daily. Cost-effectiveness analysis suggests that the point at which the costs of treatment and non-treatment were equal was 1.2 less exacerbations per year. This is higher than the effect observed in the Cochrane review, suggesting that treating everyone with COPD with mucolytic agents would not be cost effective. Those with more frequent and severe exacerbations appear to have the most to gain.Keywords
This publication has 20 references indexed in Scilit:
- Economic Burden of Chronic Obstructive Pulmonary DiseasePharmacoEconomics, 2001
- The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic reviewEuropean Respiratory Journal, 2000
- Relationship of Sputum Color to Nature and Outpatient Management of Acute Exacerbations of COPDChest, 2000
- Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ, 2000
- Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trialsClinical Therapeutics, 2000
- Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Controlled Trial of Oral Prednisone in Outpatients With Acute COPD ExacerbationAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Assessing the Quality of Randomized Controlled Trials:Current Issues and Future DirectionsInternational Journal of Technology Assessment in Health Care, 1996
- Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary DiseaseAnnals of Internal Medicine, 1987
- Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium.Thorax, 1984